Who owns CURIS INC (CRIS)? Elite investor 13F holders
2 tracked elite investors reported holding CURIS INC as of 2026-06-30, including Renaissance Technologies LLC, Maverick Capital. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma.…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | CURIS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 74123.00 USD | 141972.000000 | Shares | reduce | Original filing |
| Maverick Capital | CURIS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 6194.00 USD | 49554.000000 | Shares | hold | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.